Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 338-351

  Ferroni, Patrizia ^a   Della Morte, David ^a,b,c   Pileggi, Antonello ^c,d   Riondino, Silvia ^a   Rundek, Tatjana ^c   Ricordi, Camillo ^c,d,e   Guadagni, Fiorella ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Diabetes Research Institute   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e University of Miami College of Engineering   (United States)

Author keywords

Atherosclerosis; Haemostasis; Platelet activation; PPAR ; PPAR agonists; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 2 RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CYCLOOXYGENASE 2; ENDOTHELIN 1; FRACTALKINE; GLIMEPIRIDE PLUS METFORMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METFORMIN PLUS PIOGLITAZONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; THROMBOXANE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; BLADDER CANCER; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DEATH; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUID RETENTION; HEART FAILURE; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SIDE EFFECT; THROMBOSIS; VASCULITIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; HEMOSTASIS; HEMOSTATIC DISORDERS; HUMANS; HYPOGLYCEMIC AGENTS; PLATELET ACTIVATION; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84878633491     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030008     Document Type: Review

References (160)

1. Lüscher TF, Creager MA. Diabetes and vascular disease. Patho-physiology, clinical consequences and medical therapy. Circulation 2003; 108: 1655-1661.
2. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001; 14: 475-486.
3. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hypergly-caemic damage. Nature 2000; 404: 787-790.
4. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622.
5. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-1291.
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
7. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
8. Tripodi A, Branchi A, Chantarangkul V, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 2011; 31: 165-172.
9. Ferroni P, Della-Morte D, Pileggi A, et al. Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay. Cardiovasc Drugs Ther 2012; 26: 301-309.
10. Coppola L, Verrazzo G, La Marca C, et al. Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus. Diabet Med 1997; 14: 959-963.
11. Davì G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholes-terolemia, and hypertension but not vascular disease per se are as sociated with persistent platelet activation in vivo-evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
12. D'Angelo A, Micossi P, Mannucci PM, Garimberti B, Franchi F, Pozza G. Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes. Relationship to vascular complications. Eur J Clin Invest 1984; 14: 83-86.
13. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774.
14. Oskarsson HJ, Hofmeyer TG. Platelets from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilation. J Am Coll Cardiol 1996; 27: 1464-1470.
15. Davì G, Rini GB, Averna M, et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb Res 1982; 26: 359-370.
16. Modesti PA, Fortini A, Gensini GF, Vanni D, Prisco D, Abbate R. Human prostacyclin platelet receptors in diabetes mellitus. Thromb Res 1991; 63: 541-548.
17. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator activated receptors and inflammation. Pharmacol Ther 2005; 110: 371-385.
18. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-774.
19. Yanase T, Yashiro T, Takitani K, et al. Differential expression of PPARγ1 and γ2 isoforms in human adipose tissue. Biochem Bio-phys Res Commun 1997; 233: 320-34.
20. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002; 103: 22-33.
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
22. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the Cardiovascular System. Antioxid Redox Signal 2009; 11: 1415-1452.
23. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435.
24. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
25. Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARS. Science 2003; 302: 453-457.
26. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor a in mice. Neuro-sci Lett 2003; 352: 203-206.
27. ADA Position Statement. Standards of Medical Care in Diabetes-2012. Diabetes Care 2012; 35: S11-S63.
28. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-332.
29. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003; 27: 147-161.
30. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
31. Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271: 212-216.
32. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
33. Ek J, Andersen G, Urhammer SA, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001; 44: 1170-1176.
34. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro 12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806-1808.
35. Ek J, Urhammer SA, Sørensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro 12 Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895.
36. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
37. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959.
38. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.
39. Bodary PF, Vargas FB, King SAD, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 3: 2149-2153.
40. Chaudhuri A, Rosenstock J, DiGenio A, et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012; 28: 258-267.
41. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. Curr Drug Targets 2011; 12: 1498-1512.
42. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009; 8: 15-32.
43. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
44. Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012; 345: e4541.
45. Clyne M. Bladder cancer: Pioglitazone increases risk of bladder cancer. Nat Rev Urol 2012; 9: 353.
46. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011; 10: 419-428.
47. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23: 205-215.
48. Ali FY, Davidson SJ, Moraes LA, et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 2006; 20: 326-328.
49. Ray DM, Spinelli SL, Pollock SJ, et al. Peroxisome Proliferator-Activated Receptor y and Retinoid X Receptor transcription factors are released from activated human platelets and shed in microparti-cles. Thromb Haemost 2008; 99: 86-95.
50. Ruggeri ZM, Mendolicchio GL. Adhesion Mechanisms in Platelet Function. Circ Res 2007; 100: 1673-1685.
51. Lowenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010; 68: 242-251.
52. Ferroni P, Vazzana N, Riondino S, Cuccurullo C, Guadagni F, Davì G. Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxid Redox Signal. 2012 May 8. [Epub ahead of print]
53. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 16: 58-83.
54. Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003; 102: 1701-1707.
55. Li Z, Delaney MK, O'Brien KA, and Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-2349.
56. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404.
57. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem1985; 260: 11107-11114.
58. Peerschke EI. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost 1995; 73: 862-867.
59. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-252.
60. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-1368.
61. Hishinuma T, Yamazaki T, Mizugaki M. Troglitazone has a reducing effect on thromboxane production. Prostaglandins Other Lipid Mediat 2000; 62: 135-143.
62. Moraes LA, Spyridon M, Kaiser WJ, et al. Non-genomic effects of PPARc ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost 2010; 8: 577-587.
63. Mongan J, Mieszczanska HZ, Smith BH, Messing SP, Phipps RP, Francis CW. Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study. Thromb Res 2012; 129: 760-764.
64. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc Natl Acad Sci USA 2003; 100: 131-136.
65. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 2005; 102: 2340-2345.
66. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-812.
67. Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs 2006; 20: 231-241.
68. Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A. Review of the Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor y Agonists on Platelet Function. Diab Tech Ther 2007; 9: 410-420.
69. Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907-912.
70. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546-551.
71. Sumita C, Maeda M, Fujio Y, et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet-activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004; 1673: 115-121.
72. Eligini S, Banfi C, Brambilla M, et al. 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 2002; 88: 524-532.
73. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-339.
74. Golledge J, Mangan S, Clancy P. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Stroke 2007; 38: 1501-1508.
75. Neri T, Cordazzo C, Carmazzi Y, et al. Effects of peroxisome proliferator-activated receptor-y agonists on the generation of mi-croparticles by monocytes/macrophages. Cardiovasc Res 2012; 94: 537-544.
76. Takano H, Komuro I. Peroxisome Proliferator-Activated Receptor y and Cardiovascular Diseases. Circ J 2009; 73: 214-220.
77. Marx N. PPARgamma and vascular inflammation: adding another piece to the puzzle. Circ Res 2002; 91: 373-374.
78. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001; 12: 511-518.
79. Lowell BB. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999; 99: 239-242.
80. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102: 9406-9411.
81. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-4560S.
82. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
83. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-7619.
84. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
85. Finn AV, Nakano M, Narula J, Kolodgie FD, Birmani R. Concept of Vulnerable/Unstable Plaque. Arterioscler Thromb Vasc Biol 2010; 30: 1282-1292.
86. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
87. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103.
88. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone. Am J Hypertens 2000; 13: 74-82.
89. DeDios ST, Bruemmer D, Dilley RJ, et al. Inhibitory activity of clinical thiazolidinediones peroxisome proliferator activating receptor y ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107: 2548-2550.
90. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6: 137-143.
91. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macro-phage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-1120.
92. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-710.
93. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
94. Park KG, Lee KM, Chang YC, et al. The ascochlorin derivative, AS-6, inhibits TNF-alpha-induced adhesion molecule and chemokine expression in rat vascular smooth muscle cells. Life Sci 2006; 80: 120-126.
95. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. J Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 2002; 91: 427-33.
96. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-1905.
97. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000; 407: 227-235.
98. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302.
99. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-2104.
100. Nawa T, Nawa MT, Cai Y, et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 2000; 275: 406-411.
101. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
102. Rezvan A, Ni CW, Alberts-Grill N, Jo H. Animal, in vitro, and ex vivo models of flow-dependent atherosclerosis: role of oxidative stress. Antioxid Redox Signal 2011; 15: 1433-1448.
103. Bouallegue A, Bou Daou G, Srivastava AK. Endothelin-1-Induced Signaling Pathways in Vascular Smooth Muscle Cells. Curr Vasc Pharmacol 2007; 5: 45-52.
104. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
105. Kim S, Iwao H. Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases. Pharmacol Rev 2000; 52: 11-34.
106. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
107. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway. FASEB J 2007; 21: 950-961.
108. Zhong Duan S, Usher MG, Mortensen RM. Peroxisome Proliferator-Activated Receptor-y-Mediated Effects in the Vasculature. Circ Res 2008; 102: 283-294.
109. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-240.
110. Lazar MA. Progress in cardiovascular biology: PPAR for the course. Nat Med 2001; 7: 23-24.
111. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-58.
112. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101: 2411-2417.
113. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161-171.
114. Sugden MC, Caton PW, Holness MJ. PPAR control: it's SIRTainly as easy as PGC. J Endocrinol 2010; 204: 93-104.
115. Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 959-967.
116. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS: Plei-otropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-1108.
117. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat 1998; 12: 181-186.
118. Kato K, Yamada D, Midorikawa S, Sato W, Watanabe T. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 2000; 49: 662-665.
119. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-669.
120. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69: 5-13.
121. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
122. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: e25.
123. Chu JW, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Tsao PS. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res 2005; 2: 37-41.
124. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957.
125. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: 646-650.
126. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of thiazolidinediones. Circulation 2003; 107: 2664-2669.
127. Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Car-diol 2006; 48: 2531-2538.
128. Khanolkar MP, Morris RH, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008; 197: 718-724.
129. Sobel BE, Hardison RM, Genuth S, et al. Profibrinolytic, anti-thrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2011; 124: 695-703.
130. Schöndorf T, Musholt PB, Hohberg C, et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol 2011; 5: 426-432.
131. Yener S, Comlekci A, Akinci B, et al. Soluble CD40 ligand, plas-minogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Med Princ Pract 2009; 18: 266-271.
132. Chokesuwattanaskul W, Yaqub Y, Suarez JA, et al. Effect of pio-glitazone on platelet aggregation in a healthy cohort. Cardiology 2010; 116: 253-256.
133. Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43: 511-518.
134. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Van-houtte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-974.
135. van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets 2010; 14: 1029-1045.
136. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998; 28: 1024-1031.
137. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917.
138. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
139. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Naka-mura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
140. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
141. Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglita-zone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009; 58: 739-745.
142. Zhou M, Xu H, Pan L, Wen J, Liao W, Chen K. Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice. Eur J Pharmacol 2008; 590: 297-302.
143. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-1514.
144. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-1535.
145. Takagi T, Okura H, Kobayashi Y, et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv 2009; 2: 524-531.
146. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796-799.
147. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclaz-ide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41-46.
148. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on gly-cemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
149. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
150. Kaku K, Enya K, Sugiura K, Totsuka N. Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. Curr Med Res Opin 2011; 27 (Suppl 3):73-84.
151. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43: 661-666.
152. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994; 24: 170-175.
153. Geng DF, Wu W, Jin DM, Wang JF, Wu YM. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 2006; 113: 86-91.
154. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In mac-roVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
155. Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive 19). Clin Endocrinol Metab 2010; 95: 2163-2171.
156. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38.
157. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824-831.
158. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418.
159. Soskic SS, Dobutovic BD, Sudar EM, et al. Peroxisome proliferator-activated receptors and atherosclerosis. Angiology 2011; 62: 523-534.
160. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2549.